MX339830B - Modificacion de adenovirus recombinante con epitopes de proteina de circumsporozoito deplasmodium inmunogenico. - Google Patents
Modificacion de adenovirus recombinante con epitopes de proteina de circumsporozoito deplasmodium inmunogenico.Info
- Publication number
- MX339830B MX339830B MX2012002131A MX2012002131A MX339830B MX 339830 B MX339830 B MX 339830B MX 2012002131 A MX2012002131 A MX 2012002131A MX 2012002131 A MX2012002131 A MX 2012002131A MX 339830 B MX339830 B MX 339830B
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant adenovirus
- adenovirus
- plasmodium circumsporozoite
- protein
- modification
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 7
- 108700005482 Protozoan circumsporozoite Proteins 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 2
- 210000000234 capsid Anatomy 0.000 abstract 2
- 229940124735 malaria vaccine Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000013600 plasmid vector Substances 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 230000003263 anti-adenoviral effect Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000009145 protein modification Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2009/054212 WO2011022002A1 (en) | 2009-08-18 | 2009-08-18 | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
| PCT/US2010/045952 WO2011022522A1 (en) | 2009-08-18 | 2010-08-18 | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012002131A MX2012002131A (es) | 2012-04-11 |
| MX339830B true MX339830B (es) | 2016-06-13 |
Family
ID=43607237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002131A MX339830B (es) | 2009-08-18 | 2010-08-18 | Modificacion de adenovirus recombinante con epitopes de proteina de circumsporozoito deplasmodium inmunogenico. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170348405A1 (OSRAM) |
| EP (2) | EP3412306A3 (OSRAM) |
| JP (2) | JP5947719B2 (OSRAM) |
| KR (1) | KR20120094469A (OSRAM) |
| CN (2) | CN103025349B (OSRAM) |
| BR (1) | BR112012003808A2 (OSRAM) |
| CA (1) | CA2769415A1 (OSRAM) |
| IL (1) | IL217709A (OSRAM) |
| MX (1) | MX339830B (OSRAM) |
| NZ (1) | NZ598703A (OSRAM) |
| PH (1) | PH12012500164A1 (OSRAM) |
| RU (1) | RU2585228C2 (OSRAM) |
| SG (2) | SG10201404970PA (OSRAM) |
| UA (1) | UA108081C2 (OSRAM) |
| WO (2) | WO2011022002A1 (OSRAM) |
| ZA (1) | ZA201201286B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9115205B2 (en) | 2010-10-18 | 2015-08-25 | The United States Of America, As Represented By The Secretary Of The Army | Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression |
| US20120244178A1 (en) * | 2011-03-25 | 2012-09-27 | Denise Doolan | Plasmodium falciparum antigens |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| CN105431535A (zh) * | 2013-06-03 | 2016-03-23 | Vlp治疗有限责任公司 | 疟疾疫苗 |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| US9968665B2 (en) * | 2015-09-16 | 2018-05-15 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| LT3405582T (lt) * | 2016-01-21 | 2020-12-10 | Janssen Vaccines & Prevention B.V. | Patobulinta vakciną nuo maliarijos adenoviruso, koduojančio ir eksponuojančio maliarijos antigeną, pagrindu |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| CN107841513B (zh) * | 2016-09-18 | 2023-04-14 | 中国科学院上海巴斯德研究所 | 基于M2e表位的广谱型流感疫苗 |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN108192876A (zh) * | 2017-12-07 | 2018-06-22 | 东莞市第八人民医院 | 一种人3型腺病毒衣壳蛋白同时展示ca16双中和抗原表位疫苗候选株的制备方法和应用 |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| WO2020221451A1 (en) * | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Antibodies binding to plasmodium circumsporozoite protein and uses thereof |
| CN110687289B (zh) * | 2019-10-17 | 2023-04-18 | 中国人民解放军陆军军医大学 | Fgl2蛋白作为疟疾感染标志物的应用 |
| GB201915905D0 (en) * | 2019-11-01 | 2019-12-18 | Spybiotech Ltd | Viruses with modified capsid proteins |
| JP2021178021A (ja) * | 2020-05-14 | 2021-11-18 | 株式会社三洋物産 | 遊技機 |
| US20240240203A1 (en) * | 2021-05-04 | 2024-07-18 | SpyBiotech Limited | Adenoviral vectors and vaccines thereof |
| AU2022349649A1 (en) * | 2021-09-23 | 2024-04-04 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
| CN120944926B (zh) * | 2025-10-15 | 2026-01-30 | 华中科技大学同济医学院附属同济医院 | 衣壳表面展示超大片段抗原的重组腺病毒、构建方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066623A (en) * | 1993-11-23 | 2000-05-23 | The United States Of America As Represented By The Secretary Of The Navy | Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines |
| JP2005500336A (ja) * | 2001-07-25 | 2005-01-06 | ニューヨーク・ユニバーシティ | 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用 |
| EP2277533B1 (en) * | 2002-10-23 | 2016-07-20 | GlaxoSmithKline Biologicals S.A. | Methods for vaccinating against malaria |
| WO2004055187A1 (en) * | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| AU2004238979B2 (en) * | 2003-05-14 | 2008-12-18 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Broadening adenovirus tropism |
| JP2005287309A (ja) * | 2004-03-31 | 2005-10-20 | Dnavec Research Inc | 遺伝子導入を増強するための薬剤および方法 |
| ES2358523T3 (es) * | 2004-10-13 | 2011-05-11 | Crucell Holland B.V. | Vectores adenovirales mejorados y usos de los mismos. |
| AU2006284756B2 (en) * | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2008140474A1 (en) * | 2006-10-26 | 2008-11-20 | Johns Hopkins University | Recombinant adenovirus vaccines |
-
2009
- 2009-08-18 WO PCT/US2009/054212 patent/WO2011022002A1/en not_active Ceased
-
2010
- 2010-08-18 CA CA2769415A patent/CA2769415A1/en not_active Abandoned
- 2010-08-18 MX MX2012002131A patent/MX339830B/es active IP Right Grant
- 2010-08-18 KR KR1020127006889A patent/KR20120094469A/ko not_active Ceased
- 2010-08-18 PH PH1/2012/500164A patent/PH12012500164A1/en unknown
- 2010-08-18 CN CN201080047059.6A patent/CN103025349B/zh not_active Expired - Fee Related
- 2010-08-18 JP JP2012525677A patent/JP5947719B2/ja not_active Expired - Fee Related
- 2010-08-18 UA UAA201203125A patent/UA108081C2/ru unknown
- 2010-08-18 EP EP18168155.2A patent/EP3412306A3/en not_active Withdrawn
- 2010-08-18 CN CN201510745347.3A patent/CN105770880A/zh active Pending
- 2010-08-18 RU RU2012110255/10A patent/RU2585228C2/ru not_active IP Right Cessation
- 2010-08-18 NZ NZ598703A patent/NZ598703A/en not_active IP Right Cessation
- 2010-08-18 EP EP10810576.8A patent/EP2467157A4/en not_active Withdrawn
- 2010-08-18 SG SG10201404970PA patent/SG10201404970PA/en unknown
- 2010-08-18 SG SG2012011144A patent/SG178476A1/en unknown
- 2010-08-18 BR BR112012003808A patent/BR112012003808A2/pt not_active IP Right Cessation
- 2010-08-18 WO PCT/US2010/045952 patent/WO2011022522A1/en not_active Ceased
-
2012
- 2012-01-24 IL IL217709A patent/IL217709A/en not_active IP Right Cessation
- 2012-02-21 ZA ZA2012/01286A patent/ZA201201286B/en unknown
-
2016
- 2016-03-03 JP JP2016041230A patent/JP6293181B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-30 US US15/419,523 patent/US20170348405A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170348405A1 (en) | 2017-12-07 |
| EP2467157A4 (en) | 2014-01-22 |
| MX2012002131A (es) | 2012-04-11 |
| EP3412306A3 (en) | 2019-01-02 |
| EP3412306A2 (en) | 2018-12-12 |
| JP2013502221A (ja) | 2013-01-24 |
| IL217709A0 (en) | 2012-03-29 |
| NZ598703A (en) | 2014-04-30 |
| WO2011022522A1 (en) | 2011-02-24 |
| BR112012003808A2 (pt) | 2016-11-16 |
| JP2016146837A (ja) | 2016-08-18 |
| CA2769415A1 (en) | 2011-02-24 |
| CN103025349A (zh) | 2013-04-03 |
| HK1179508A1 (zh) | 2013-10-04 |
| ZA201201286B (en) | 2013-05-29 |
| SG178476A1 (en) | 2012-03-29 |
| PH12012500164A1 (en) | 2022-03-09 |
| AU2010286187A1 (en) | 2012-02-16 |
| UA108081C2 (uk) | 2015-03-25 |
| CN105770880A (zh) | 2016-07-20 |
| EP2467157A1 (en) | 2012-06-27 |
| IL217709A (en) | 2016-05-31 |
| CN103025349B (zh) | 2016-05-18 |
| JP5947719B2 (ja) | 2016-07-06 |
| SG10201404970PA (en) | 2014-10-30 |
| WO2011022002A1 (en) | 2011-02-24 |
| RU2012110255A (ru) | 2013-09-27 |
| KR20120094469A (ko) | 2012-08-24 |
| JP6293181B2 (ja) | 2018-03-14 |
| RU2585228C2 (ru) | 2016-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012500164A1 (en) | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes | |
| IL263249B (en) | A polypeptide isolated from btv virus which causes an immune response in an animal and a polypeptide containing a DNA segment that codes for an epitope or an antigenic determinant of the btv polypeptide | |
| MX347997B (es) | Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle. | |
| WO2001091536A3 (en) | Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens | |
| WO2003072719A3 (en) | Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences | |
| MX346245B (es) | Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria. | |
| JP2016146837A5 (OSRAM) | ||
| MX2022009167A (es) | Formulaciones para vacuna contra coronavirus. | |
| WO2004096993A3 (en) | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus | |
| ATE526411T1 (de) | Avirulente, immunogene flavivirus-chimäre | |
| WO2010068968A8 (en) | Methods and compositions for use of a coccidiosis vaccine | |
| EP3077408A1 (en) | Molecular adjuvant | |
| MX344103B (es) | Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle. | |
| WO2010044919A3 (en) | Smallpox dna vaccine and the antigens therein that elicit an immune response | |
| SI2538972T1 (en) | Recombinant CDV compositions and their uses | |
| AU2023258457B2 (en) | Live-attenuated flaviruses with heterologous antigens | |
| WO2008086386A3 (en) | Adenoviral vector-based malaria vaccines | |
| WO2012118559A3 (en) | Tetravalent and mixed head bivalent dengue vaccine | |
| JP2019506168A5 (OSRAM) | ||
| MX354752B (es) | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. | |
| AR081409A1 (es) | PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV) | |
| PH12013500122A1 (en) | Parapoxvirus vectors | |
| Pulido et al. | RNA immunization can protect mice against foot-and-mouth disease virus | |
| WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same | |
| WO2008127307A3 (en) | Induction of an immune response against dengue virus using prime-boost approach |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |